iFAST Diagnostics Ltd secures first commercial order

iFAST Diagnostics Ltd is delighted to have secured their first multi-system commercial sale with long standing partner UKHSA.

UKHSA have placed an order for three new iFAST Rapid Antimicrobial Susceptibility Testing systems for use in the Countermeasure Development Evaluation and Preparedness Division labs, as scientists pursue significant projects to develop and evaluate new antimicrobials.

UKHSA has been working with iFAST Diagnostics since the company was founded in early 2023 and first used a prototype iFAST instrument as part of NIHR-funded research partnership, led by UKHSA and the University of Southampton, looking to develop rapid susceptibility tests for combating AMR – antimicrobial resistance.

With important early partners such as UKHSA, iFAST Diagnostics was able to develop highly accurate instruments that have since been clinically tested to now report on antimicrobial susceptibility in a precise, low cost, and time efficient way.

As the company prepares to launch into the UK market early in 2026, the revolutionary IFASTONE instruments will give full qualitative S/I/R results (Sensitive, Intermediate, Resistant) and quantitative MIC (Minimum Inhibitory Concentration) results in under 3 hours, creating opportunities for actionable clinical outcomes and in the case at UKHSA, important research insights, all within a single laboratory working shift.

In a clinical setting the speed and detail of response improves patient outcomes and helps to combating AMR, by enabling clinicians to give the best drug every time.

The high-volume turnaround of the research-grade iFAST AST systems, being purchased by UKHSA, allows for faster throughput of therapeutic evaluation studies as well as providing important insights into bacterial population structures, in a range of drug-resistant pathogens.

The iFAST machines will be used by UKHSA, Porton Down, in two specific areas of research 
  • The development and evaluation of new phage therapies (bacteriophages, or phages for short), other phage-derived biologics and novel small molecule therapies.
  • To validate additional further applications for iFAST including fungal infections and STD’s

Quote from Dr. Toby King, CEO of iFAST Diagnostics Ltd: “This is a significant milestone for iFAST Diagnostics, progressing our long-term partnership with UKHSA, and moving this into a commercial relationship, whilst continuing to jointly focus on the urgent need for low-cost, same day antimicrobial susceptibility testing”

Quote from Professor J. Mark Sutton, Scientific Leader, UKHSA: “We are excited to expand the use of iFAST technology at UKHSA to help in the all-important mission of combating AMR in our work to support health security in the United Kingdom.”

iFAST expects imminent ISO 13485 Quality Management System certification and looks forward to launching the system for clinical use in the UK at the start of 2026

iFAST Diagnostics, 1500 Parkway, Whiteley, Hampshire PO15 7AF, United Kingdom

FOLLOW US:

Scroll to Top